- Piramal Pharma reported a consolidated net loss of Rs 69.4 crore for Q1 FY27
- Revenue rose 17.4% year-on-year to Rs 2,270 crore in the quarter ended June 30
- EBITDA increased 82.9% to Rs 195 crore compared to Rs 107 crore last year
Piramal Pharma Ltd. reported a narrower consolidated net loss for the first quarter of FY27, supported by double-digit revenue growth and a sharp improvement in operating margins.
The company posted a consolidated net loss of Rs 69.4 crore for the quarter ended June 30, compared with a loss of Rs 81.7 crore in the corresponding period last year, according to the company's quarterly earnings filing.
Revenue from operations rose 17.4% year-on-year to Rs 2,270 crore, up from Rs 1,934 crore a year earlier.
ALSO READ: Star Health Q1 Results: Profit Surges 26% To Rs 550 Crore; Insurance Revenue Rises
Operating performance improved significantly during the quarter. Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 82.9% to Rs 195 crore, compared with Rs 107 crore in the year-ago period.
The company's EBITDA margin expanded to 8.6%, from 5.5% in the corresponding quarter last year, reflecting stronger operating leverage and improved profitability.
Piramal Pharma Q1 (Consolidated, YoY)
• Net Loss at Rs 69.4 crore versus loss of Rs 81.7 crore
• Revenue up 17.4% to Rs 2,270 crore versus Rs 1,934 crore
• Ebitda up 82.9% to Rs 195 crore versus Rs 107 crore
• Ebitda Margin at 8.6% versus 5.5%
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
